Effects of NR1I2 and ABCB1 Genetic Polymorphisms on Everolimus Pharmacokinetics in Japanese Renal Transplant Patients
Authors:
Open Access
- 3 October 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 11742
Abstract
The purpose of this study was to evaluate the effects of NR1I2 (7635G>A and 8055C>T) and ABCB1 (1236C>T, 2677G>T/A, and 3435C>T) genetic polymorphisms on everolimus pharmacokinetics in 98 Japanese renal transplant patients. On day 15 after everolimus administration, blood samples were collected just prior to and 1, 2, 3, 4, 6, 9, and 12 h after administration. The dose-adjusted area under the blood concentration–time curve (AUC0-12) of everolimus was significantly lower in patients with the NR1I2 8055C/C genotype than in those with other genotypes (p = 0.022) and was significantly higher in male patients than female patients (p = 0.045). Significant correlations between the dose-adjusted AUC0-12 of everolimus and age (p = 0.001), aspartate transaminase (p = 0.001), and alanine transaminase (p = 0.005) were found. In multivariate analysis, aging (p = 0.008) and higher alanine transaminase levels (p = 0.032) were independently predictive of a higher dose-adjusted everolimus AUC0-12. Aging and hepatic dysfunction in patients may need to be considered when evaluating dose reductions in everolimus. In renal transplant patients, management using everolimus blood concentrations after administration may be more important than analysis of NR1I2 8055C>T polymorphism before administration.Keywords
Funding Information
- Japan Society for the Promotion of Science (20K07150)
This publication has 32 references indexed in Scilit:
- Population Pharmacokinetics and Pharmacogenetics of Everolimus in Renal Transplant PatientsClinical Pharmacokinetics, 2012
- Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantationTransplant International, 2012
- CYP3A5 Genotype Does Not Influence Everolimus In Vitro Metabolism and Clinical Pharmacokinetics in Renal Transplant RecipientsTransplantation, 2011
- Optimal Everolimus Concentration Is Associated With Risk Reduction for Acute Rejection in De Novo Renal Transplant RecipientsTransplantation, 2010
- Multicenter, Randomized Study of the Use of Everolimus With Tacrolimus After Renal Transplantation Demonstrates its EffectivenessTransplantation, 2008
- MDR1 gene polymorphisms and risk of recurrence in patients With hepatocellular carcinoma after liver transplantationJournal of Surgical Oncology, 2007
- The Pregnane X Receptor Locus Is Associated With Susceptibility to Inflammatory Bowel DiseaseGastroenterology, 2006
- Genetic polymorphisms influencing xenobiotic metabolism and transport in patients with primary biliary cirrhosisHepatology, 2004
- Mechanisms of Clinically Relevant Drug Interactions Associated with TacrolimusClinical Pharmacokinetics, 2002
- Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by RifampinJournal of Biological Chemistry, 2001